198 related articles for article (PubMed ID: 25421470)
1. Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.
Hope WW; Kaibara A; Roy M; Arrieta A; Azie N; Kovanda LL; Benjamin DK
Antimicrob Agents Chemother; 2015 Feb; 59(2):905-13. PubMed ID: 25421470
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
Undre NA; Stevenson P; Freire A; Arrieta A
Pediatr Infect Dis J; 2012 Jun; 31(6):630-2. PubMed ID: 22301478
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.
Benjamin DK; Deville JG; Azie N; Kovanda L; Roy M; Wu C; Arrieta A
Pediatr Infect Dis J; 2013 Nov; 32(11):e419-25. PubMed ID: 23958810
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
6. Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!
Gumbo T
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S635-42. PubMed ID: 26567282
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
Autmizguine J; Hornik CP; Benjamin DK; Brouwer KL; Hupp SR; Cohen-Wolkowiez M; Watt KM
Pediatr Infect Dis J; 2016 Nov; 35(11):1204-1210. PubMed ID: 27314826
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of micafungin in neonates and young infants.
Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
[TBL] [Abstract][Full Text] [Related]
9. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Hope WW; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.
Auriti C; Falcone M; Ronchetti MP; Goffredo BM; Cairoli S; Crisafulli R; Piersigilli F; Corsetti T; Dotta A; Pai MP
Antimicrob Agents Chemother; 2016 Dec; 60(12):7333-7339. PubMed ID: 27697761
[TBL] [Abstract][Full Text] [Related]
12. [Micafungin in invasive candidiasis among oncohematological patients].
Jarque I; Angel Sanz M
Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis.
Undre N; Stevenson P; Baraldi E
Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):31-8. PubMed ID: 21956255
[TBL] [Abstract][Full Text] [Related]
14. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
Carter NJ; Keating GM
Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
[TBL] [Abstract][Full Text] [Related]
15. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
16. [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].
Montejo M; Quindós G
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():15-22. PubMed ID: 21420572
[TBL] [Abstract][Full Text] [Related]
17. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.
Hope WW; Seibel NL; Schwartz CL; Arrieta A; Flynn P; Shad A; Albano E; Keirns JJ; Buell DN; Gumbo T; Drusano GL; Walsh TJ
Antimicrob Agents Chemother; 2007 Oct; 51(10):3714-9. PubMed ID: 17638696
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation.
Albano E; Azie N; Roy M; Townsend R; Arrieta A
J Pediatr Hematol Oncol; 2015 Jan; 37(1):e45-50. PubMed ID: 25072363
[TBL] [Abstract][Full Text] [Related]
20. [Why might micafungin be the drug of choice in pediatric patients?].
Ramos Amador JT; Prieto Tato L; Guillén Martín S
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
